...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacogenomics >Pharmacogenetics of selective serotonin reuptake inhibitors in pediatric depression and anxiety
【24h】

Pharmacogenetics of selective serotonin reuptake inhibitors in pediatric depression and anxiety

机译：选择性5-羟色胺再摄取抑制剂在小儿抑郁症和焦虑症中的药代动力学

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Selective serotonin reuptake inhibitors (SSRIs) are now an accepted and widely used first-line treatment for pediatric depression and anxiety. However, the data indicate that SSRI treatment achieves a clinical response in only 55–60% of children, and some may develop drug-induced suicidal behavior. Clinicians have no reliable tools to help them identify in advance those youths who are not likely to respond to an SSRI, or who are likely to develop SSRI-induced suicidality. Pharmacogenetic research attempts to identify genetic markers that are associated with response and side-effect profile. This review covers all the pharmacogenetic studies conducted as yet on pediatric samples and compares them with available data on adult samples. An emphasis is put on serotonergic genes such as the serotonin transporter (5-HTT) and additional genes known to be active in the CNS.
机译：选择性5-羟色胺再摄取抑制剂（SSRIs）现已成为小儿抑郁症和焦虑症的一种被广泛接受的一线治疗方法。但是，数据表明SSRI治疗仅在55-60％的儿童中达到了临床反应，有些可能发展为药物引起的自杀行为。临床医生没有可靠的工具来帮助他们提前识别那些不太可能对SSRI做出反应或可能发展为SSRI诱导的自杀倾向的年轻人。药物遗传学研究试图确定与反应和副作用有关的遗传标记。这篇综述涵盖了迄今对儿科样本进行的所有药物遗传学研究，并将其与成人样本的现有数据进行了比较。重点放在5-羟色胺转运蛋白（5-HTT）等血清素能基因上，以及已知在CNS中有活性的其他基因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号